Please use this identifier to cite or link to this item:
|Title:||Analysis of corrections following regulatory inspections|
Attard Pizzuto, Maresca
Zarb Adami, Maurice
Azzopardi, Lilian M.
|Keywords:||Pharmaceutical industry -- Malta -- Quality control|
Pharmaceutical industry -- European Union countries -- Quality control
Pharmaceutical industry -- Inspection
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Debono, A., Attard Pizzuto, M., Zarb Adami, M., & Azzopardi, L. M. (2018, March). Analysis of corrections following regulatory inspections. Poster session presented at the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spain.|
|Abstract:||A poster presentation regarding the analysis of corrections following regulatory inspections. Introduction: A good quality system ensures that the medicinal product’s quality is maintained throughout the whole lifecycle, safeguarding patient’s well-being. The European Union (EU) lays down directives for Member States to ensure that quality levels are achieved. GMP and GDP inspections are undertaken by regulatory agencies to ensure compliance with the EU Directives. Aims: To analyse the corrections resulting from GMP/GDP regulatory inspections carried out by the regulatory authority on manufacturers and wholesalers.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Analysis_of_corrections_following_regulatory_inspections_2018.pdf||317.81 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.